tiprankstipranks
Helus Pharma (HELP)
NASDAQ:HELP
US Market
HELP
Helus Pharma
RESEARCH TOOLSreports

Helus Pharma (HELP) Earnings Dates, Call Summary & Reports

2,500 Followers

Earnings Data

Report Date
Aug 06, 2026
Before Open (Confirmed)
Period Ending
2027 (Q1)
Consensus EPS Forecast
―
Last Year’s EPS
-1.08
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Nov 13, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.
Company Guidance
In the recent call, Cybin provided several key metrics and updates regarding their ongoing programs and financial status. The company has raised $175 million in recent financing, aiming to advance their lead programs, CYB003 and CYB004, towards significant data readouts. CYB003, a deuterated psilocin analog, is in Phase III for major depressive disorder and has expanded its global footprint, targeting 330 participants across approximately 60 clinical sites. CYB004, targeting generalized anxiety disorder, has completed Phase II enrollment, with top-line data expected in Q1 2026. For the fiscal quarter ending September 30, 2025, Cybin reported cash-based operating expenses of $28.5 million and a net loss of $33.7 million. The company ended the quarter with $83.8 million in cash, cash equivalents, and investments, projecting these funds to support operations into 2027. Cybin emphasizes a disciplined approach to capital deployment, focusing on measurable milestones, global site activations, and manufacturing readiness to ensure successful execution of their clinical and commercial strategies.
Advancement in Clinical Programs
CYB003 Phase III program for major depressive disorder and CYB004 Phase II program for generalized anxiety disorder are progressing as planned. The CYB004 study completed enrollment and is on track for a top line readout in the first calendar quarter of 2026.
Successful Financing and Strengthened Capital Position
Closed a $175 million financing, providing flexibility to execute plans and retire convertible debentures. Ended the quarter with $83.8 million in cash, cash equivalents, and investments.
Global Study Expansion
EMBRACE Phase III study for CYB003 has been cleared to commence in the United States, U.K., multiple European Union countries, and Australia.
Operational and Commercial Readiness
Partnership with Thermo Fisher for manufacturing and Osmind for point-of-care software to enhance clinic workflow and data management.
Positive Market and Investor Confidence
Participation from prominent institutional healthcare investors in recent financing reflects confidence in Cybin's science and programs.

Helus Pharma (HELP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

HELP Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2026
2027 (Q1)
- / -
-1.083―――
Jun 29, 2026
2026 (Q4)
-0.81 / -0.94
-1.0268.49% (+0.09)――
Feb 13, 2026
2026 (Q3)
-0.73 / -0.96
-0.373-157.17% (-0.59)――
Nov 13, 2025
2026 (Q2)
-1.02 / -1.33
-2.0133.71% (+0.68)―
Aug 13, 2025
2026 (Q1)
- / -
-0.534―――
Jul 01, 2025
2025 (Q4)
-0.92 / -1.08
-0.534-102.76% (-0.55)――
Feb 11, 2025
2025 (Q3)
-0.74 / -0.37
-2.40484.50% (+2.03)――
Nov 13, 2024
2025 (Q2)
-0.93 / -2.01
-1.335-50.53% (-0.67)――
Aug 08, 2024
2025 (Q1)
-0.93 / -0.53
-1.8771.43% (+1.34)――
Jun 26, 2024
2024 (Q4)
-1.07 / -1.20
-1.8735.71% (+0.67)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

HELP Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jun 29, 2026
$6.48$6.88+6.17%
Feb 13, 2026
$5.92$6.09+2.87%
Nov 13, 2025
$6.46$5.94-8.05%
Aug 13, 2025
$7.60$7.17-5.66%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Helus Pharma (HELP) report earnings?
Helus Pharma (HELP) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
    What is Helus Pharma (HELP) earnings time?
    Helus Pharma (HELP) earnings time is at Aug 06, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is HELP EPS forecast?
          Currently, no data Available